A Combined Two-mRNA Signature Associated With PD-L1 and Tumor Mutational Burden for Prognosis of Lung Adenocarcinoma

A Combined Two-mRNA Signature Associated With PD-L1 and Tumor Mutational Burden for Prognosis of Lung Adenocarcinoma

Due to biological heterogeneity, lung adenocarcinoma (LUAD) patients with the same stage may exhibit variable responses to immunotherapy and a wide range of outcomes. It is urgent to seek a biomarker that can predict the prognosis and response to immunotherapy in these patients. In this study, we id...

Full description

Bibliographic Details
Main Authors: Congkuan Song, Zhiquan Wu, Qingwen Wang, Yujin Wang, Zixin Guo, Sheng Li, Weidong Hu
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-01-01
Series:Frontiers in Cell and Developmental Biology
Subjects:
lung adenocarcinoma
immunotherapy
prognosis
tumor mutational burden
PD-L1
Online Access:https://www.frontiersin.org/articles/10.3389/fcell.2021.634697/full

Internet

https://www.frontiersin.org/articles/10.3389/fcell.2021.634697/full

Similar Items